series-b
Stage
1
Investors
About
Chemomab Therapeutics is a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the CCL24 protein to treat fibro-inflammatory diseases including liver, skin, and lung fibrosis.
Explore Chemomab Therapeutics Ltd.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.